AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6354422 — intervention group
Group type: EXPERIMENTAL
Intervention: Superfractionation (SF) radiation therapy (4000 rad in 45 fractions in 3 weeks whole brain and 1000 rad in five fractions in one week local boost)
Number of subjects: 69
Study 6354422 — intervention group
Group type: COMPARATOR
Intervention: Conventional Fractionation (CF) radiation therapy (3400 rad in 17 fractions whole brain in 3.5 weeks and 1600 rad in eight fractions in 1.5 weeks local boost)
Number of subjects: 69
Study 6354422 — intervention group
Group type: EXPERIMENTAL
Intervention: Superfractionation (SF) radiation therapy
Number of subjects: 69
Study 31282028 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg)
Number of subjects: 9340
Study 31282028 — intervention group
Group type: COMPARATOR
Intervention: Placebo (plus standard of care therapy)
Number of subjects: 9340
Study 29432959 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 SQ‐HDM (sublingual immunotherapy tablet)
Number of subjects: 1272
Study 29432959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1272
Study 25248311 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet
Number of subjects: 90
Study 25248311 — intervention group
Group type: COMPARATOR
Intervention: No Tourniquet
Number of subjects: 90
Study 24128654 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon consumption (two 150 g portions of farmed salmon per week from 20 weeks of pregnancy to delivery)
Number of subjects: 123
Study 24128654 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon group infants
Number of subjects: 123
Study 24128654 — intervention group
Group type: COMPARATOR
Intervention: Control group (habitual diet)
Number of subjects: 123
Study 22397774 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedoanalgesia
Number of subjects: 100
Study 22397774 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprostatic blockage (PPB)
Number of subjects: 100
Study 22397774 — intervention group
Group type: COMPARATOR
Intervention: Intrarectal gel instillation
Number of subjects: 100
Study 18629526 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg venlafaxine
Number of subjects: 40
Study 18629526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17604558 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture group (EG)
Number of subjects: 30
Study 17604558 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 30
Study 15848575 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Neoral (day 0)
Number of subjects: 197
Study 15848575 — intervention group
Group type: COMPARATOR
Intervention: Delayed Neoral (day 6)
Number of subjects: 197
Study 11882931 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO+intravenous iron (EPO+IV)
Number of subjects: 21
Study 11882931 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO+oral iron (EPO+OR)
Number of subjects: 21
Study 11882931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 11882931 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO (both groups)
Number of subjects: 21
Study 10531077 — intervention group
Group type: EXPERIMENTAL
Intervention: DMARD and prednisolone (mean dose 6 mg, mean cumulated dose 2160 mg)
Number of subjects: 76
Study 10531077 — intervention group
Group type: COMPARATOR
Intervention: DMARD alone
Number of subjects: 76
Study 10531077 — intervention group
Group type: EXPERIMENTAL
Intervention: DMARD and prednisolone
Number of subjects: 76
Study 7789045 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol
Number of subjects: 8
Study 7789045 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg
Number of subjects: 8
Study 7789045 — intervention group
Group type: COMPARATOR
Intervention: Inhibition of angiotensin-converting enzyme (lisinopril)
Number of subjects: 8
Study 2112177 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.5 to 1.0 mg)
Number of subjects: 0
Study 2112177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 483170 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 27
Study 483170 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacids
Number of subjects: 27
Study 30327952 — intervention group
Group type: EXPERIMENTAL
Intervention: Brush-off patch containing 3.0% hydrogen peroxide applied for 10 min twice daily (case 10 group)
Number of subjects: 140
Study 30327952 — intervention group
Group type: EXPERIMENTAL
Intervention: Brush-off patch containing 3.0% hydrogen peroxide applied for 30 min once daily (case 30 group)
Number of subjects: 140
Study 30327952 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 140
Study 29211893 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (8-week period)
Number of subjects: 78
Study 29211893 — intervention group
Group type: COMPARATOR
Intervention: Lean participants
Number of subjects: 78
Study 29211893 — intervention group
Group type: COMPARATOR
Intervention: Abdominally obese participants
Number of subjects: 78
Study 26918556 — intervention group
Group type: COMPARATOR
Intervention: Miglitol (50 mg) just before breakfast (intake schedule B)
Number of subjects: 0
Study 26918556 — intervention group
Group type: COMPARATOR
Intervention: Miglitol dissolved in water (50 mg) taken just before, during, and just after breakfast (intake schedule C)
Number of subjects: 0
Study 26918556 — intervention group
Group type: EXPERIMENTAL
Intervention: No miglitol (intake schedule A)
Number of subjects: 0
Study 24128798 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-stage method (SSM)
Number of subjects: 134
Study 24128798 — intervention group
Group type: COMPARATOR
Intervention: Descriptive teaching method
Number of subjects: 134
Study 21930328 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 3117
Study 21930328 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 3117
Study 21930328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3117
Study 21930328 — intervention group
Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 3117
Study 21930328 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg (ACCEPT trial)
Number of subjects: 3117
Study 21930328 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg (ACCEPT trial)
Number of subjects: 3117
Study 20133410 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-recruitment confirmation of informed consent by SMS
Number of subjects: 553
Study 17993823 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotrafilcon A lenses
Number of subjects: 53
Study 17993823 — intervention group
Group type: COMPARATOR
Intervention: Balafilcon A lenses
Number of subjects: 53
Study 17993823 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily-wear basis
Number of subjects: 53
Study 17993823 — intervention group
Group type: COMPARATOR
Intervention: Continuous-wear basis
Number of subjects: 53
Study 16390409 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir prophylaxis for 100 days
Number of subjects: 381
Study 16390409 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir prophylaxis for 100 days
Number of subjects: 381
Study 12447737 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal carriage among older siblings in DCCs
Number of subjects: 36
Study 12447737 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal strains from older siblings' DCCs
Number of subjects: 36
Study 12447737 — intervention group
Group type: COMPARATOR
Intervention: 7-valent pneumococcal conjugate vaccine
Number of subjects: 36
Study 10669899 — intervention group
Group type: EXPERIMENTAL
Intervention: Tettuccio mineral water
Number of subjects: 14
Study 10669899 — intervention group
Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 14
Study 7549411 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3.5 mg/kg in 200 ml)
Number of subjects: 8
Study 7549411 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.5 g/kg made up to 200 ml)
Number of subjects: 8
Study 7549411 — intervention group
Group type: COMPARATOR
Intervention: Water (200 ml)
Number of subjects: 8
Study 119270 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 15
Study 119270 — intervention group
Group type: EXPERIMENTAL
Intervention: CF 25‐397
Number of subjects: 15
Study 119270 — intervention group
Group type: COMPARATOR
Intervention: Apomorphine
Number of subjects: 15
Study 31020351 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceritinib 750 mg/day
Number of subjects: 156
Study 29080924 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 728
Study 29080924 — intervention group
Group type: COMPARATOR
Intervention: Control (treatment without panitumumab)
Number of subjects: 728
Study 26731113 — intervention group
Group type: EXPERIMENTAL
Intervention: Promitor™ Soluble Corn Fibre (SCF) at 6 g/fibre/day
Number of subjects: 24
Study 26731113 — intervention group
Group type: EXPERIMENTAL
Intervention: Promitor™ Soluble Corn Fibre (SCF) at 12 g/fibre/day
Number of subjects: 24
Study 26731113 — intervention group
Group type: EXPERIMENTAL
Intervention: Promitor™ Soluble Corn Fibre (SCF) at 18 g/fibre/day
Number of subjects: 24
Study 24117908 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-defined pharmacist care (intervention group)
Number of subjects: 734
Study 24117908 — intervention group
Group type: COMPARATOR
Intervention: Usual pharmacist care (control group)
Number of subjects: 734
Study 22004115 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 2
Study 22004115 — intervention group
Group type: COMPARATOR
Intervention: Placebo consumption
Number of subjects: 2
Study 18679401 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal irrigation using Peristeen Anal Irrigation
Number of subjects: 0
Study 18679401 — intervention group
Group type: COMPARATOR
Intervention: Conservative bowel management
Number of subjects: 0
Study 18679401 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal irrigation
Number of subjects: 0
Study 17374331 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate therapy
Number of subjects: 0
Study 17374331 — intervention group
Group type: COMPARATOR
Intervention: PUVA therapy
Number of subjects: 0
Study 17374331 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PUVA to methotrexate
Number of subjects: 0
Study 15650986 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine HCl (1 mg/mL) with an infusion rate of 0.3 mg/h and 1‐mg bolus doses
Number of subjects: 75
Study 15650986 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (50 microg/mL) with an infusion rate of 1 microg/kg/h and 10‐microg bolus
Number of subjects: 75
Study 15650986 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (50 microg/mL) with an infusion rate of 0.05 microg/kg/min and 0.5‐microg/kg bolus
Number of subjects: 75
Study 11173324 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 25
Study 11173324 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 25
Study 11173324 — intervention group
Group type: COMPARATOR
Intervention: H pylori-positive DU patients
Number of subjects: 25
Study 11173324 — intervention group
Group type: EXPERIMENTAL
Intervention: Cure of H pylori
Number of subjects: 25
Study 11173324 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects
Number of subjects: 25
Study 10968183 — intervention group
Group type: COMPARATOR
Intervention: Closed reduction and splint immobilization
Number of subjects: 28
Study 10968183 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation
Number of subjects: 28
Study 8150634 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde venous perfusion (RVP) with netilmycin, once/day for 10 days
Number of subjects: 45
Study 8150634 — intervention group
Group type: COMPARATOR
Intervention: Systemic venous infusions (SVI) with netilmycin, three times/day for 10 days
Number of subjects: 45
Study 3254824 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 40
Study 3254824 — intervention group
Group type: COMPARATOR
Intervention: Cholestyramine
Number of subjects: 40
Study 3254824 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin + Cholestyramine
Number of subjects: 40
Study 29373242 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) cream 0.05%
Number of subjects: 54
Study 29373242 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 54
Study 27197727 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmeatal low‐level laser therapy for tinnitus
Number of subjects: 54
Study 27197727 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry assessment
Number of subjects: 54
Study 24479529 — intervention group
Group type: EXPERIMENTAL
Intervention: Male avatar in competitive setting against two female avatars
Number of subjects: 120
Study 24479529 — intervention group
Group type: COMPARATOR
Intervention: Female avatar in competitive setting against two male avatars
Number of subjects: 120
Study 24479529 — intervention group
Group type: EXPERIMENTAL
Intervention: Male avatar in cooperative setting
Number of subjects: 120
Study 24479529 — intervention group
Group type: COMPARATOR
Intervention: Female avatar in cooperative setting
Number of subjects: 120
Study 22641777 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training for 3 months
Number of subjects: 19
Study 22641777 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 healthy sedentary individuals)
Number of subjects: 19
Study 20176167 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary fixation (Gamma nail, Stryker Howmedica; Endovis BA, Citieffe)
Number of subjects: 120
Study 20176167 — intervention group
Group type: COMPARATOR
Intervention: Dynamic hip screw and plate (DHS, Synthes‐Stratec)
Number of subjects: 120
Study 18312937 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernosal saline infusion
Number of subjects: 33
Study 18312937 — intervention group
Group type: COMPARATOR
Intervention: Control (no infusion)
Number of subjects: 33
Study 16151336 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETA) 25 mg SC twice weekly for 8 weeks
Number of subjects: 20
Study 16151336 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 20
Study 16151336 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETA)
Number of subjects: 20
Study 12063369 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber pacing
Number of subjects: 2010
Study 12063369 — intervention group
Group type: COMPARATOR
Intervention: Ventricular pacing
Number of subjects: 2010
Study 10490438 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg triptorelin intramuscularly every four weeks (group 1)
Number of subjects: 46
Study 10490438 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group 2)
Number of subjects: 46
Study 8628471 — intervention group
Group type: EXPERIMENTAL
Intervention: Coagulant or antiaggregant therapy, surgical closure of PFO
Number of subjects: 140
Study 8628471 — intervention group
Group type: EXPERIMENTAL
Intervention: Interatrial communication, recent migraine history, posterior cerebral artery territory infarct, coexisting cause of stroke
Number of subjects: 140
Study 8628471 — intervention group
Group type: EXPERIMENTAL
Intervention: Interatrial septum aneurysm (ISA)
Number of subjects: 140
Study 8628471 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment type (coagulant or antiaggregant therapy, surgical closure of PFO)
Number of subjects: 140
Study 8351156 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine (TZD)
Number of subjects: 10
Study 8351156 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 10
Study 3524513 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic treatment by a speech pathologist for 12 weeks, followed by 12 weeks of no treatment
Number of subjects: 0
Study 3524513 — intervention group
Group type: EXPERIMENTAL
Intervention: Home treatment by a trained volunteer for 12 weeks, followed by 12 weeks of no treatment
Number of subjects: 0
Study 3524513 — intervention group
Group type: COMPARATOR
Intervention: Deferred treatment for 12 weeks, followed by 12 weeks of treatment by a speech pathologist
Number of subjects: 0
Study 29973664 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord milking (UCM) performed during even months (cord milked three times)
Number of subjects: 101
Study 29973664 — intervention group
Group type: COMPARATOR
Intervention: Control group (no UCM) during odd months
Number of subjects: 101
Study 26924488 — intervention group
Group type: EXPERIMENTAL
Intervention: SASA! community mobilisation intervention
Number of subjects: 351
Study 25454938 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated adjustment of FiO2
Number of subjects: 15
Study 25454938 — intervention group
Group type: COMPARATOR
Intervention: Manual adjustment of FiO2
Number of subjects: 15
Study 23548995 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling intervention focused on promoting totally smoke‐free homes and cars (TSFHC) with self‐help booklet and three gifts; 110 women received this intervention.
Number of subjects: 218
Study 23548995 — intervention group
Group type: COMPARATOR
Intervention: Self‐help booklet promoting TSFHC; all participants received this.
Number of subjects: 218
Study 22099904 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoVac (EV)
Number of subjects: 10
Study 22099904 — intervention group
Group type: EXPERIMENTAL
Intervention: Rispi-Sonic/MicroMega 1500 (MM)
Number of subjects: 10
Study 22099904 — intervention group
Group type: EXPERIMENTAL
Intervention: Syringe irrigation with a slot-tipped needle (SN)
Number of subjects: 10
Study 22099904 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive ultrasonic irrigation (PUI)
Number of subjects: 10
Study 22099904 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoActivator (EA)
Number of subjects: 10
Study 22099904 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 10
Study 19508159 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose (HD) trivalent, inactivated influenza vaccine (60 microg of hemagglutinin per strain)
Number of subjects: 3837
Study 19508159 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose (SD) trivalent, inactivated influenza vaccine (15 microg of hemagglutinin per strain)
Number of subjects: 3837
Study 19508159 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose (HD) trivalent, inactivated influenza vaccine
Number of subjects: 3837
Study 16817038 — intervention group
Group type: EXPERIMENTAL
Intervention: ACKD present in 48 (55.8%) patients; 24 (50%) had grade 1 ACKD and 24 (50%) had grade 2 ACKD.
Number of subjects: 86
Study 16817038 — intervention group
Group type: EXPERIMENTAL
Intervention: AH detected before HD in 68 (79.1%) patients and after HD in 54 (62.8%) patients.
Number of subjects: 86
Study 16817038 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of dialysis treatment.
Number of subjects: 86
Study 16817038 — intervention group
Group type: EXPERIMENTAL
Intervention: Diameter of the inferior vena cava measured three hours after HD.
Number of subjects: 86
Study 12614804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent antegrade warm blood cardioplegia (IAWBC) at 33 degrees C
Number of subjects: 200
Study 12614804 — intervention group
Group type: COMPARATOR
Intervention: Intermittent antegrade cold blood cardioplegia at 4 degrees C
Number of subjects: 200
Study 10688090 — intervention group
Group type: EXPERIMENTAL
Intervention: SS-cream 0.20 g
Number of subjects: 106
Study 10688090 — intervention group
Group type: COMPARATOR
Intervention: Placebo 0.20 g
Number of subjects: 106
Study 7593873 — intervention group
Group type: EXPERIMENTAL
Intervention: Demandingness during interactions
Number of subjects: 48
Study 7593873 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal during interactions
Number of subjects: 48
Study 7593873 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal by men and woman demand-man withdraw during discussions identified by women
Number of subjects: 48
Study 1903404 — intervention group
Group type: COMPARATOR
Intervention: recombinant tissue-type plasminogen activator (rt-PA)
Number of subjects: 108
Study 1903404 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 108
Study 7045440 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin (10-day courses, repeated whenever susceptible bacteriuria was present)
Number of subjects: 35
Study 7045440 — intervention group
Group type: COMPARATOR
Intervention: Control (no antibiotic treatment)
Number of subjects: 35
Study 7045440 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin
Number of subjects: 35
Study 30244979 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle joint mobilization
Number of subjects: 77
Study 30244979 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar massage
Number of subjects: 77
Study 30244979 — intervention group
Group type: EXPERIMENTAL
Intervention: Triceps surae stretching
Number of subjects: 77
Study 30244979 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study 28253033 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 517
Study 26419293 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 3-12 mg/d
Number of subjects: 1037
Study 26419293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1037
Study 24047339 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy (62-70 Gy in 31-35 fractions)
Number of subjects: 1476
Study 24047339 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (62-70 Gy in 31-35 fractions)
Number of subjects: 1476
Study 21332937 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-times faster infusion rate delivery (FIRD)
Number of subjects: 0
Study 21332937 — intervention group
Group type: COMPARATOR
Intervention: Slower infusion rate delivery (SIRD)
Number of subjects: 0
Study 19919768 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT) for asymptomatic children aged <6 years
Number of subjects: 220
Study 19919768 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for tuberculosis (TB) disease
Number of subjects: 220
Study 16913429 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexpected impact (4.5 m/s2)
Number of subjects: 29
Study 16913429 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexpected impact (10.1 m/s2)
Number of subjects: 29